Hongkui Deng
邓宏魁
Hongkui Deng is a Peking University Boya Chair Professor and lead scientist at Changping Laboratory, recognized for pioneering work in cellular reprogramming . He earned his PhD from UCLA in 1995 and completed postdoctoral research at New York University . Deng developed the first chemical-method approach to reprogram somatic cells into pluripotent stem cells (CiPSC), circumventing the genetic-integration risks of the earlier transcription-factor method; his lab demonstrated CiPSC-derived islets improving diabetes in non-human primates by 2022 . In 2024 he received the Future Science Prize in Life Sciences for these contributions . He is also chief scientist at BeiCell Therapeutics, a ZhenFund-backed startup founded in 2022 to develop CiPSC-based cell therapies , and was named to TIME's 2025 TIME100 Health list .
AI-generated — may contain errors, please verify.
Coverage
A Whole New World | Z News
We invite you to look back on the past month's "highlight reel" — a look at how our portfolio companies have grown and what's new at ZhenFund.
Greener Pastures, First Flickers of Ambition | Z News
The light and shadow grow richer; a story is brewing.
2024 Future Science Prize Winners Announced | Z News
Celebrating scientists and honoring the spirit of scientific inquiry.
